NERVGEN PHARMA CORP.
NERVGEN PHARMA CORP. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury on July 15, 2027. There is 1 upcoming event on record.
Cash runway is approximately 13.6 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| July 15, 2027 | A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury | Trial Milestone | Phase 3 |
Track NGEN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NGEN in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.